Hotchkis & Wiley Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.99M	Buy	84,420 +1,370	+2%	+$110K	0.02%	362
2026 Q1	$6.39M	Buy	83,050 +8,270	+11%	+$645K	0.02%	348
2025 Q4	$5.9M	Buy	74,780 +320	+0.4%	+$27.7K	0.02%	379
2025 Q3	$6.82M	Sell	74,460 -12,150	-14%	-$991K	0.02%	326
2025 Q2	$5.65M	Sell	86,610 -21,990	-20%	-$1.43M	0.02%	380
2025 Q1	$7.27M	Buy	108,600 +51,420	+90%	+$3.07M	0.02%	296
2024 Q4	$3.16M	Buy	57,180 +5,100	+10%	+$293K	0.01%	438
2024 Q3	$3.11M	Buy	+52,080	New	+$3.18M	0.01%	444

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hotchkis & Wiley Capital Management's ANIP Position: Q2 2026 in Review

Hotchkis & Wiley Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 1.6% in Q2 2026, buying an estimated $110K and bringing the position to 84,420 shares worth $6.99M. The position accounts for 0.02% of the portfolio, ranked #362.

Hotchkis & Wiley Capital Management first reported a position in ANIP in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.27M in Q1 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Hotchkis & Wiley Capital Management held 84,420 shares of ANI Pharmaceuticals worth $6.99M as of Q2 2026.
Hotchkis & Wiley Capital Management bought 1,370 ANI Pharmaceuticals shares in Q2 2026, an estimated $110K.
ANI Pharmaceuticals made up 0.02% of Hotchkis & Wiley Capital Management's portfolio in Q2 2026, its #362 holding.
Hotchkis & Wiley Capital Management first reported a position in ANI Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Hotchkis & Wiley Capital Management's ANI Pharmaceuticals position peaked at $7.27M in Q1 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.